Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Five Patent Issues That European Biosimilar Developers Should Consider Before Entering The US Market (<em>European Pharmaceutical Review</em>)

main

06_22 Five Patent Issues That European Biosimilar

Five Patent Issues That European Biosimilar Developers Should Consider Before Entering The US Market ( European Pharmaceutical Review ) | News & Events | Goodwin

Five Patent Issues That European Biosimilar Developers Should Consider Before Entering The US Market (European Pharmaceutical Review)

Related Content

Four Steps to Maximize the Value of AI Innovation in Medtech

Are AI Inventions Harder to Patent?

FDA Platform Technology Draft Guidance Highlights Utility of Obscure Patent Term Extension Provision

USPTO Issues Further Guidance on AI-Related Patent Eligibility

The Rapid Rise of AI, in Five Charts

The Appeals Review Panel’s In Re Xencor Decision: The USPTO Provides Its Position on Written Description and Means-Plus-Function Claims

USPTO’s New Guidance on AI-Assisted Inventions: The Impact on the Use of AI in the Life Sciences

USPTO Issues New Guidance on Patenting AI-Assisted Inventions

US & EP Data Exclusivity: Same Name, Different Games

Eight Goodwin Partners Named 2025 IAM Global Leaders

Goodwin Advises HLTH in its Acquisition by Hyve

A Legal Tug of War on Hemp-Derived Cannabinoid Regulations (Cannabis Business Times)

Zip Closes $190 Million Series D, Largest Funding Round in AI-Powered Procurement Orchestration Sector

Goodwin UK Highly Ranked in Chambers UK 2025

Reliance on Third-Party "Pricing" Facilitators Is Under Increasing Antitrust Scrutiny (Intellectual Property& Technology Law Journal)

Benchmark Litigation US 2025 Recognizes 45 Goodwin Litigators

Life Sciences

Intellectual Property

Complex Litigation & Dispute Resolution

Litigation